Cover Image

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors

Abstract Oraxol consists of an oral dosage form of the chemotherapeutic agent paclitaxel administered with a novel P‐glycoprotein inhibitor encequidar methanesulfonate monohydrate (formerly named HM30181A), which allows oral treatment of cancers that would otherwise be treated with intravenous pacli...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jimmy He (Author), Christopher G. C. A. Jackson (Author), Sanjeev Deva (Author), Tak Hung (Author), Katriona Clarke (Author), Eva Segelov (Author), Tsu‐Yi Chao (Author), Ming‐Shen Dai (Author), Hsien‐Tang Yeh (Author), Wen Wee Ma (Author), Douglas Kramer (Author), Wing‐Kai Chan (Author), Rudolf Kwan (Author), David Cutler (Author), Jay Zhi (Author)
Format:	Book
Published:	Wiley, 2022-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
by: Lazzaro C, et al.
Published: (2013)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
by: De Luca R, et al.
Published: (2018)

A case of metastatic basal cell carcinoma treated with carboplatin and paclitaxel
by: Chryssoula Papageorgiou, et al.
Published: (2023)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
by: Kundranda MN, et al.
Published: (2015)

Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer
by: Masafumi Yasunaga, et al.
Published: (2022)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
by: Dranitsaris G, et al.
Published: (2015)

A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy
by: Fumie Hanawa, et al.
Published: (2011)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Clinical trials and progress with paclitaxel in ovarian cancer
by: Sanjeev Kumar, et al.
Published: (2010)

Brain targeted delivery of paclitaxel using endogenous ligand
by: Sanjeev R. Acharya, et al.
Published: (2016)

Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer
by: Dandan Ling, et al.
Published: (2024)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
by: Palumbo R, et al.
Published: (2015)

A Rare Case of Recurrent Metastatic Solid Pseudopapillary Neoplasm of the Pancreas
by: Hye Seung Lee, et al.
Published: (2017)

Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
by: Sirui Tan, et al.
Published: (2022)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
by: Nan Zhou, et al.
Published: (2023)

Hedgehog Suppresses Paclitaxel Sensitivity by Regulating Akt-Mediated Phosphorylation of Bax in EGFR Wild-Type Non-Small Cell Lung Cancer Cells
by: Yun-Chieh Tu, et al.
Published: (2022)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022)

Pharmacokinetic evaluation of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration
by: Yoontaek Lee, et al.
Published: (2024)

Anti-lung cancer effect of paclitaxel solid lipid nanoparticles delivery system with curcumin as co-loading partner in vitro and in vivo
by: Chao Pi, et al.
Published: (2022)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
by: Leonid Gibiansky, et al.
Published: (2022)

Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment
by: Wing-Hin Lee, et al.
Published: (2020)

Physicochemical Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion Bags
by: Helen Linxweiler, et al.
Published: (2024)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data
by: Chengcheng Gong, et al.
Published: (2022)

Paclitaxel-induced pseudoscleroderma
by: Krzysztof Sadko, et al.
Published: (2023)

The dark side of paclitaxel
by: Alekha K. Dash
Published: (2011)

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
by: Chaitali Passey, et al.
Published: (2023)

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study
by: Swapna Kochuveettil, et al.
Published: (2024)

Paclitaxel-related nail toxicity
by: Szu-Ting Yang, et al.
Published: (2019)

Management of paclitaxel-induced neurotoxicity
by: Manisha Bhutani, et al.
Published: (2011)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
by: Cinzia Borghese, et al.
Published: (2020)

Paclitaxel: new uses for an old drug
by: Zhang D, et al.
Published: (2014)

Berberine Alleviates Paclitaxel-Induced Neuropathy
by: Ramin Rezaee, et al.
Published: (2019)

Effects of Piperazine Derivative on Paclitaxel Pharmacokinetics
by: Jaeok Lee, et al.
Published: (2019)

Solubilization Methods for Paclitaxel and Docetaxel: An Overview
by: Fariba Pourkarim, et al.
Published: (2022)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020)

Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients
by: Zhenhua Du, et al.
Published: (2015)

Enhancing Paclitaxel Efficacy with Piperine-Paclitaxel Albumin Nanoparticles in Multidrug-Resistant Triple-Negative Breast Cancer by Inhibiting P-Glycoprotein
by: Wenwen Xu, et al.
Published: (2023)

Acute localized exanthematous pustulosis induced by paclitaxel
by: Ana Carolina Tardin Rodrigues de Medeiros, et al.
Published: (2022)